<SEC-DOCUMENT>0000950170-22-009670.txt : 20220512
<SEC-HEADER>0000950170-22-009670.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512161212
ACCESSION NUMBER:		0000950170-22-009670
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		22917930

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(425) 620-8501

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>atha-20220512.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-05-12T11:25:16.7511+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:atha="http://athira.com/20220512" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_52e8f171-ac48-4fe5-a2c0-dabeb0dfc465" name="dei:AmendmentFlag" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric id="F_5d21fadd-21e5-40f8-8f16-66cb87413e05" name="dei:EntityCentralIndexKey" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a">0001620463</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atha-20220512.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_72a7fe5e-3498-4d66-be85-930574d9811a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-12</xbrli:startDate><xbrli:endDate>2022-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Wingdings;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="agm_results"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Washington, DC 20549</span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c050076-fcfa-44f6-b8b3-5b4172356730" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed872b65-829a-4c70-88b8-394e03bab28d" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">May 12, 2022</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_639411ca-213a-42fb-a1d1-055fd2852ad1" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.34%;"></td>
    <td style="width:33.34%;"></td>
    <td style="width:33.32%;"></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93914722-d546-4b04-8151-525843b4e3f1" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_794c4f27-51dd-4380-8008-5a3664b9dc29" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">001-39503</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24c3692b-f2b4-4076-83d6-01d95a2e7700" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">45-3368487</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:20.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(State or other jurisdiction</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Commission</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a348824-bc21-4e4b-a3f4-5bf47eb9ef43" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18706 North Creek Parkway</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b993a0ad-9017-42b1-887c-156cffa85f43" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Suite 104</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br /></span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70720b98-0eea-487d-8daf-be4380cd0140" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Bothell</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84cc91ea-c011-4bab-8472-109b3b2204b2" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">WA</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_360076d2-def5-40f2-b5d5-074315b4166f" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">98011</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53162c24-cf8e-4eee-86e7-ed4145c1292a" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">425</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21e5445c-936c-4187-b7f1-0a9d108d653f" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">620-8501</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.521%;"></td>
    <td style="width:96.479%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b27a5cd-05ec-42ac-8325-a395783802e6" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9167a419-f600-4f09-ac78-98cb1a280e92" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ad79437-f353-4bd9-afa4-d6f11728cc91" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d017f7c-5370-4bf1-9d32-fa03d1a8b0d2" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.998%;"></td>
    <td style="width:30.004%;"></td>
    <td style="width:34.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f171ebd7-45bf-4a8c-81b6-6a659f7e9a47" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9999f1d9-e632-4886-89c3-6b4feef0566d" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">ATHA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c593f70f-f938-4923-9ddd-d478ad65cdcf" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;<br />(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.0%;"></td>
    <td style="width:75.0%;"></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a67752e-b5d3-4530-ba16-f9535224403a" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:0.9199999999999998;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).  </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3392c808-fdef-4dbc-804c-c785950cdd4f" contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Wingdings;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On May 12, 2022, Athira Pharma, Inc. (the &#x201c;Company&#x201d;) issued a press release reporting its financial results for the quarter ended March 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">tem 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#x2019;s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its Twitter account (@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.002%;"></td>
    <td style="width:1.005%;"></td>
    <td style="width:89.993%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;border-bottom:1.000pt solid;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;border-bottom:1.000pt solid;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="atha-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc. press release dated May 12, 2022</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:2.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The information furnished in this Current Report under Items 2.02 and 7.01 and the exhibit attached hereto shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5.004%;"></td>
    <td style="width:44.996%;"></td>
    <td style="width:5.004%;"></td>
    <td style="width:44.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.042in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">May 12, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;border-bottom:1.000pt solid;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ Mark Litton</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Mark Litton</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.38;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>atha-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img247042425_0.jpg" alt="img247042425_0.jpg" style="width:174px;height:86px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Calibri;min-width:fit-content;">Athira Pharma Reports First Quarter 2022 Financial Results</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Calibri;min-width:fit-content;"> and Provides Pipeline and Business Updates</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">On track to report topline data from ACT-AD Phase 2 Alzheimer&#x2019;s disease study by end of 2Q22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">BOTHELL, WA, May 12, 2022</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> &#x2014; </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira Pharma, Inc.</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company&#x2019;s financial resumlts for the quarter ended March 31, 2022 and provided pipeline and business updates.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#x201c;Throughout the first quarter of 2022 we made significant progress advancing our strategy across Athira&#x2019;s clinical development programs, with a focus on bringing our lead drug candidate, fosgonimeton, and the other molecules in our pipeline to patients while continuing to create lasting shareholder value,&#x201d; stated Mark Litton, Ph.D., MBA, President and Chief Executive Officer of Athira. &#x201c;During the first quarter, we published and presented a growing body of clinical and preclinical evidence in support of targeting the HGF/MET neurotrophic system.  We were pleased to initiate two new studies in the first quarter: the Phase 2 SHAPE study of fosgonimeton in Parkinson&#x2019;s disease dementia and Dementia with Lewy Bodies and a Phase 1 study of ATH-1020 to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#x201c;In addition to our considerable clinical progress, we advanced our corporate strategy through the expansion of our senior management team, as well as the expansion of our Board of Directors with two talented industry leaders &#x2013; Grant Pickering, a proven life sciences leader with over 30 years of experience across all stages of corporate and clinical development, and Dr. Michael Panzara, an industry veteran with more than 20 years of CNS drug development and commercialization experience.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#x201c;We are looking forward to reporting topline data from our Phase 2 ACT-AD study in Alzheimer&#x2019;s disease by the end of 2Q22 as we expect to gain insights into the safety and efficacy of our novel intervention as well as optimize the analysis plan for our potentially pivotal LIFT-AD study.  We continue to advance these important studies in order to bring this potentially transformative medicine to the millions of patients impacted by Alzheimer&#x2019;s disease,&#x201d; concluded Dr. Litton.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">First Quarter and Recent Highlights:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:14.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Announced it is extending the ongoing Open Label Extension study for the LIFT-AD and ACT-AD clinical trials of fosgonimeton for mild-to-moderate Alzheimer&#x2019;s disease, enabling eligible patients who have completed either trial, and elect to participate in the ongoing open label extension, to now receive up to 18 months of open-label treatment with fosgonimeton;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Presented baseline Event Related Potential (ERP) P300 latency and patient demographic data from the ACT-AD study at the AD/PD&#153; conference that showed the study patient population enrolled in the Phase 2 trial is representative of the mild-to-moderate Alzheimer&#x2019;s population </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;visibility:hidden;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">and is appropriate to evaluate the effect of fosgonimeton on ERP P300 latency, a functional, objective measure of working memory processing speed</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">and executive function that highly correlates with cognition;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Highlighted preclinical data that demonstrate the mechanism of action of the active metabolite of fosgonimeton is through positive modulation of HGF/MET and results in neurotrophic and procognitive effects in an oral presentation at the American Society for Experimental Neurotherapeutics (ASENT) annual meeting; </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Presented preclinical data at ASENT showing that ATH-1020, a novel, orally available, brain-penetrant small molecule, demonstrated neuroprotective effects, mitigated depression-like behaviors and normalized an electroencephalography (EEG) hallmark of schizophrenia in animal models; </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Published results from Phase 1 clinical trial of fosgonimeton in healthy volunteers and patients with Alzheimer&#x2019;s disease in the peer-reviewed </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">Journal of Alzheimer's Disease </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">showing that fosgonimeton demonstrated a statistically significant improvement of ERP P300 latency as compared with placebo in Alzheimer&#x2019;s disease patients;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Announced fosgonimeton as the World Health Organization&#x2019;s recommended international nonproprietary name for lead product candidate ATH-1017, and the United States Adopted Names (USAN) Council has adopted fosgonimeton as a USAN; </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Dosed the first patient in the SHAPE Phase 2 clinical trial of fosgonimeton in Parkinson&#x2019;s disease dementia and Dementia with Lewy bodies; </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Dosed the first subject in a Phase 1 study of ATH-1020, designed to target neuropsychiatric conditions;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Appointed life science industry leaders Grant Pickering and Michael Panzara, M.D. to the Board of Directors; and </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Expanded the senior management team with new hires, including the addition of: </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Donald Mackenzie, Ph.D., Senior Vice President CMC and Technical Operations. Dr. Mackenzie brings more than 30 years of experience in developing and launching new medicines at GlaxoSmithKline (GSK), including 15 new medicines over the last decade; </font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Arthur Rosenthal, Vice President of Drug Regulatory Affairs. Mr. Rosenthal brings more than 30 years of regulatory experience and has a proven track record of bringing neurology products to approval at companies including Avanir Pharmaceuticals and Valeant;</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Lana Gloukhova, M.D., Vice President Drug Safety and Pharmacovigilance. Dr. Gloukhova has extensive experience leading global safety and clinical teams at multinational pharmaceutical companies including CSL Behring, AbbVie, Merck and Schering-Plough; and</font></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:14.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">o</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Simon Daggett, Vice President Clinical Operations. Mr. Daggett brings more than 30 years of drug development experience, including 19 years at Allergan. He has considerable global expertise leading all aspects of clinical studies from pre-IND through Phase 3 to approval.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Pipeline Update:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Fosgonimeton (ATH-1017)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> is a small molecule specifically designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">ACT-AD Phase 2 Study in mild-to-moderate Alzheimer&#x2019;s disease (</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">NCT04491006</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Enrollment in ACT-AD completed in October 2021 with 77 participants with mild-to-moderate Alzheimer&#x2019;s disease across 14 sites in the United States and Australia. The primary endpoint for ACT-AD is change in ERP P300 Latency, a functional, objective measure of working memory processing speed, with secondary endpoints measuring cognition, function, and behavior.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira remains on track to report top-line data by the end of the second quarter of 2022.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">ACT-AD trial is supported by a grant from the National Institute on Aging of the National Institutes of Health under Award Number R01AG06268. The information presented in this press release is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">LIFT-AD Phase 3 Study in mild-to-moderate Alzheimer&#x2019;s Disease (</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">NCT04488419</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Recruitment in the LIFT-AD trial is ongoing.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira increased the study sample size from 300 to approximately 420, in order to strengthen the statistical power of co-key secondary endpoints, including ADAS-Cog11.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">The company is targeting completion of enrollment of this potentially pivotal study in the third quarter of 2022 and top-line data in the first half of 2023.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">Open Label Extension Study (</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">NCT04886063</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">In June 2021, Athira initiated an Open Label Extension Study (OLEX). Following completion of the 26-week treatment period during the LIFT-AD or ACT-AD trials, eligible patients can elect to continue on the OLEX and receive treatment with fosgonimeton at the high dose (70 mg/day) for up to an additional 26 weeks. Investigators and patients remain blinded to treatment group assignment in the original trials.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">The company recently announced that it is extending the length of the current Open Label Extension (OLEX) study. The decision is in alignment with the independent Data and Safety Monitoring Board (DSMB) following its most recent review of available data. Eligible patients who have completed the LIFT-AD or ACT-AD trials and elect to participate in the ongoing open label extension may now receive up to 18 months of open-label treatment with fosgonimeton. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">The majority of eligible patients who have completed the LIFT-AD and ACT-AD studies have opted to participate in the OLEX.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">SHAPE Phase 2 Study in Parkinson&#x2019;s disease dementia and Dementia with Lewy bodies (</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">NCT04831281</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira dosed the first patient in the SHAPE trial in January 2022. SHAPE is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 proof-of-concept study of fosgonimeton in approximately 75 participants with Parkinson&#x2019;s disease dementia or Dementia with Lewy bodies.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">The company is targeting completion of enrollment of the SHAPE study in the first half of 2023.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">ATH-1020 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">is a novel, orally available, brain-penetrant small molecule designed to enhance the HGF/MET system that is being advanced as a potential treatment candidate for neuropsychiatric indications.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">Phase 1 Study in Healthy Volunteers (</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">NCT05169671</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira initiated a Phase 1 clinical trial for ATH-1020 in the first quarter of 2022. The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of ATH-1020 in approximately 68 healthy young and elderly volunteers.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Preclinical Data of novel HGF/MET positive modulators (ATH-1018 and ATH-1019) to be presented at Peripheral Nerve Society (PNS) 2022 Annual Meeting</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira will present new preclinical data at the upcoming PNS 2022 Annual Meeting in a poster presentation titled, &#x201c;Small Molecule HGF/MET Positive Modulator Effectively Reduces Pain-Related Behaviors in a Rat Diabetic Neuropathy Model,&#x201d; on May 15, 2022. The data are supportive of the HGF/MET mechanism and the company&#x2019;s future plans to continue exploring HGF/MET positive modulators for other therapeutic indications, including peripheral indications.<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;">Financial Results</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Cash Position</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">. Cash, cash equivalents and investments were $301.2 million as of March 31, 2022, compared with $319.7 million as of December 31, 2021. Cash used in operations was $16.6 million for the quarter ended March 31, 2022, compared with $7.3 million for the first quarter of 2021.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Research and Development (R&amp;D) Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">. R&amp;D expenses were $14.5 million for the first quarter ended March 31, 2022, compared with $7.4 million for the same period in 2021. The increase was driven primarily by costs related to increased clinical trial activities, increased personnel, and increased preclinical R&amp;D expenses.  </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">General and Administrative (G&amp;A) Expenses. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">G&amp;A expenses were $8.9 million for the first quarter ended March 31, 2022, compared with $3.3 million for the same period in 2021, primarily due to increased personnel expense associated with the company&#x2019;s headcount growth. In addition, increases to G&amp;A expenses in 2022 were the result of costs associated with the proxy solicitation in connection with the company&#x2019;s annual stockholder meeting, an increase in professional services expenses, an increase in business development expenses, and to lesser extents, increases in insurance and facilities costs. </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Net Loss</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">. Net loss was $21.0 million, or $0.56 per share, for the first quarter ended March 31, 2022, compared with a net loss of $8.9 million, or $0.25 per share, for the first quarter ended March 31, 2021. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">About Athira Pharma, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira Pharma Inc., headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates, targeting the HGF/MET neurotrophic system, for Alzheimer&#x2019;s and Parkinson&#x2019;s disease dementia, Dementia with Lewy bodies, and neuropsychiatric and peripheral indications. For more information, visit </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:Calibri;min-width:fit-content;">www.athira.com</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">. You can also follow Athira on </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Facebook</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">, </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">LinkedIn</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> and @athirapharma on </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Twitter</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> and </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Instagram</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Forward-Looking Statements</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">This release contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding fosgonimeton as a potential treatment for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease dementia, Dementia with Lewy bodies, and other dementias, and ATH-1020 as a potential treatment for neuropsychiatric indications; Athira&#x2019;s platform technology and potential therapies; future</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">development plans; clinical and regulatory objectives and the timing thereof, including the timing of the LIFT-AD and ACT-AD clinical trials and the timing of the Phase 2 clinical trial of fosgonimeton for treatment of Parkinson&#x2019;s disease dementia and Dementia with Lewy bodies; interactions with regulators and the timing thereof, including anticipated timing of IND or equivalent submissions; expectations regarding the potential efficacy and commercial potential of Athira&#x2019;s product candidates; the anticipated reporting of data; and Athira&#x2019;s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;would,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;intend,&#x201d; &#x201c;pursue,&#x201d; &#x201c;continue,&#x201d; and other similar expressions, among others. Any forward-looking statements are based on management&#x2019;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira&#x2019;s fosgonimeton product candidate from the Phase 1a/b trials will not continue or persist in current or planned clinical trials; cessation or delay of any of the ongoing clinical trials and/or Athira&#x2019;s development of fosgonimeton and other product candidates may occur; future potential regulatory milestones of our product candidates, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval;  the impact of the COVID-19 pandemic on Athira&#x2019;s business, research and clinical development plans and timelines and results of operations, including impact on Athira&#x2019;s clinical trial sites and contractors who act for or on Athira&#x2019;s behalf, may be more severe and more prolonged than currently anticipated; the regulatory process for Athira product candidates; the outcome of legal proceedings which have been or may in the future be instituted against us and certain of our directors and officers; clinical trials may not demonstrate safety and efficacy of any of Athira&#x2019;s product candidates; Athira&#x2019;s assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; Athira&#x2019;s research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira&#x2019;s product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; the impact of competition; while P300 latency is a functional measure that is highly correlated with cognition, Athira may not successfully establish a connection between these P300 latency results and improved cognition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira&#x2019;s clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira&#x2019;s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Investor &amp; Media Contact</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Julie Rathbun</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Athira Pharma</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">Julie.rathbun@athira.com</font></font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">206-769-9219</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(Unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.833%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:12.737%;"></td>
    <td style="width:0.855%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.519%;"></td>
    <td style="width:12.737%;"></td>
    <td style="width:0.855%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;">March 31,</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;">December 31,</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;">2021</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Cash and cash equivalents</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">117,811</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">110,537</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Short-term investments</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">145,715</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">143,222</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Other short-term assets</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,628</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,040</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term investments</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">37,644</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">65,936</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Other long-term assets</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">6,204</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">5,273</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total assets</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">313,002</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">332,008</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Liabilities and stockholders' equity</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Current liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,471</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">9,292</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term liabilities</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,554</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,632</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">11,025</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10,924</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Stockholders' equity</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">301,977</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">321,084</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders' equity</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">313,002</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">332,008</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Statement of Comprehensive Loss</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands, except share and per share amounts)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(Unaudited)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3225;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.833%;"></td>
    <td style="width:1.436%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:12.726%;"></td>
    <td style="width:0.985%;"></td>
    <td style="width:1.33%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:12.714%;"></td>
    <td style="width:0.012%;"></td>
    <td style="width:0.973%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;">Year Ended December 31,</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;">2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;">2021</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Research and development</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">14,460</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">7,445</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;text-indent:13.7pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:13.7pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">General and administrative</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">8,927</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">3,336</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:27.35pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:27.35pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">23,387</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">10,781</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(23,387</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(10,781</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Grant income</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">2,234</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">1,831</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Other income, net</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">173</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">84</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Net loss</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(20,980</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(8,866</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Unrealized loss on available-for-sale securities</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(1,068</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(5</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(22,048</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(8,871</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Net loss per share attributable to common stockholders,</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;basic and diluted</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(0.56</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">(0.25</font></p></td>
    <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Weighted-average shares used in computing net loss per</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;share attributable to common stockholders, basic</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;and diluted</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">37,593,328</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">35,775,454</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Arial;min-width:fit-content;"> </font>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img247042425_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img247042425_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %8 K4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJIJ-\F
MGV,ES(?NC@>I["E*2BFWL.,7)J*W.9\8:GDII\3=/FEQ^@KDZ?/.]S<232'+
MNQ)-,P< D'!Z&OE,16=:HYL^LPU%4::@@QD@#J>*]6LHQ#901C^&-1^E>7VD
M?FWL$?\ >D4?K7JP&*]+*(_'+T/,S>7P1]1:***]H\4**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N!\4ZM]NO/LL3?N(3R1_$U=#XFU<:?9>3$W^D3# _V1
MW->?YSR>M>-F>)_Y<Q^9[.68;_E]+Y$D$#W-Q'#$,NYP!6IXAM4L9[6T3_EE
M#R?4D\FMGPCI'EH=0F7YFXB![#UK*\6-NUU_9%%<CP_L\+[26\FON.Q8CVF*
M]G':*?WE/0X_,UVR7TD#?ES7IM>=>%TW>(;?T 8_^.FO1:]#*E^Z;\SSLV?[
MU+R"BBBO4/+"BBB@ HHHH ***9+(D,3RR'"(I9CZ 4 (UQ"C%7E16'8L!3?M
M=O\ \]X_^^A7SYJ^JS:GJ]U>F1P)9"5 8\+V_2J7G2_\]9/^^C72L/YF7M3Z
M326.7/ER*V.NTYI]>-?#?6&M/$7V661C'=+M^8_Q#D5[**QJ0Y'8N,N97"BB
MBH*"BBB@ HHHH **** "BBB@ HHHH *8\L<6/,=5STW'%/KSGXKNR6FG[69?
MG;H<=JJ$>:5A2=E<] ^UV_\ SWC_ .^A1]KM_P#GO'_WT*^;_.E_YZO_ -]&
MCSI?^>LG_?1K?ZOYF?M?(^E$=9%W(P9?4'-.KE?AX2W@VT+$D[GY)_VC755S
MR5G8T3NKA1112&%%%% !1110 4C$ $DX ZFEKF?'NHRZ;X3N7A8K)*1$".V>
MOZ9II7=A-V5S%\0?$V"QN'M=+MUN9$.&E<X0'V Y-8EI\5M328&[L;:6+/(C
MRK?@<FN!HKM5&"5K&#G(^A-"U^Q\067VFS<\</&WWD/H:U:\0^'FHRV7BNWA
M5CY5R#&Z^O''ZU[?7+4AR2L;0E=!1116904444 %%%% !1110 4444 %%%%
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M -]OY5Z/7G'Q9_X]-/\ ]]OY5I2^-$3^%GEM%%%=YSGM_P .O^1,M/\ >?\
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MPKSSQ6NW7I/=%->AUP7C%-NLJW]Z,5YV:*]#YGHY6[5_D0>%6V^(8!ZJX_\
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M[(3=M6=77G'Q9_X]-/\ ]]OY5W6D7<U_I5M=SQ"*2:,.4!Z9KA?BS_QZ:?\
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M<HTV[IE)S70['5OB#H>G0MY-P+N;'RI%R,^YKA](L+_Q[XG.H7RD6:,"Y_A
M'1!71Z9\*["!P^H74ESC_EF@V*?KWKN[2TM[&W2WM84BB085$& *GFC!>YN.
MSE\1*JA%"J % P .U><_%G_CTT__ 'V_E7H]8?B+PO9^)8X4NY9HQ$25\H@?
MS%13DHR394E=6/ J*]>_X55HW_/W>_\ ?2_X4?\ "JM&_P"?N]_[Z7_"NKV\
M#+V<C1^'7_(F6G^\_P#Z$:ZJL_1='@T+3(["V>1XHR2#(03R<]JT*Y).\FS9
M*R"BBBI&<K\1?^1+O/\ >3_T(5XA7T3K6D0:[I<MA</(D4A!)C(!X.>]<I_P
MJK1O^?N]_P"^E_PKHI5(QC9F4XMO0\AKT_X2?ZC5/]]/Y&K_ /PJK1O^?N]_
M[Z7_  K?\.>%K/PREPMI+-()R"WFD'&/3 %54JQE&R%&#3N;E9/B?_D6-2_Z
M]W_E6M5:_LX]0L)[.5F6.9"C%>H!KF3LS5['S=2UZ]_PJK1O^?N]_P"^E_PH
M_P"%5:-_S]WO_?2_X5V>W@8^SD8'PI_Y#5Y_UQ'\Z]:KG/#W@VP\-W4MQ:37
M#M(NTB4@C'X"NCKFJR4I71K!-*S(Y_\ CWE_W#_*OFR7_72?[Q_G7TLZAT93
MT88KAF^%>C,Q8W=[DG/WE_PJJ,U"]R9Q;V/(*Z?X>_\ ([6/TD_] -=O_P *
MJT;_ )^[W_OI?\*OZ-X TS0]5BU"WN+IY8LX61E(Y&.P]ZUE6BXM$J#3.LHH
MHKD-@HHHH 9)&LL;1R*&1@0RGH17C/B_P1<Z+<27=E&TNGL<C R8O8^WO7M-
M(RA@00"#U!JX3<'H3**D?,]:6@ZW<:!JL=];\X^5T/1U[BO7-7^'NAZH[2I$
MUI,W): X!^J]*Y:Z^$]TI/V74HG'_31"/Y5TJM"2LS+DDMCL-*\<:'J<*G[6
MEO*>L<QVD&M*;7](@3=)J5LJ^OF UY<WPNUL$@2VQ'KN-3V_PIU-V'GWEM&O
M? )-9.%/N7S3[&YXB^)5E;0/#I!^T7!&!*1\B>_O7F]]IM]%8PZI>!A]KD;:
M7^\_<M7JVB_#C2-,D6:YW7LR\CS!\@/^[_C6KXA\*V7B2*WCNI)HE@)*^40.
MOU%.-2$':(G&4MSP.BO7O^%5:-_S]WO_ 'TO^%'_  JK1O\ G[O?^^E_PK7V
M\"?9R-+X=_\ (EV7U?\ ]"-=36?HND0:'I<6GV[R/%'G!D()Y.>U:%<DG>39
MLE9!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#.UC28M5LS&V!*O,;]P?\ "O-[BWDM;AX)E*R(<$5ZS6#XDT0:C;^?  +F
M,<?[8]*\W'X/VJ]I#XE^)Z>7XSV4O9S^%_@<EI6I?95FM9B6M;A"KC^Z2."*
MS2,$C.<4$$$@C!'4&BO!E-N*B^A[T8)2<EU.S\%W6ZUGM2>4;</H:ZJO.O#%
MW]FUJ-2<+*"A_I7HM?0Y=4YZ"7;0^=S*GR5V^^H4445WG %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Q/BO1O(D^WP+^[<XD ['UKF*]9FA2XA>&10
MR.""#7FFK:<^EW[P-DIU1O45X&8X7V<O:1V?YGT&6XKVD?9RW7Y%*.1HI5D0
MX9&# ^XKU:TN%N[.&X3[LB!J\HKN?!UYYVFO;,?FA;CZ&C*ZO+4<'U%FM+FI
MJ:Z'24445[YX 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% #)&*1NPZ@$UY(WQ5UE78?9+'@X^ZW_P 57K4_^HD_W3_*OGO1
MHHY_$=E%*@>-[@!E/0C-;T8Q:=S.HVK6.J7XKZQN^:SLB/0!A_6M72_BM').
ML>IV'E(>#+"V<?4'_&NQ;PKH+*1_95K^"5P/CWP79Z78#5--4Q(KA98NHP>A
M'XTTZ<G:PFIK6YZA;7,-Y;I<6\BR1.,JRG@BH=6NWL-'O;R,*SP0/(H;H2%)
MYKAOA5J4DMI>:?(Q982'CSV!ZC\Z[+Q'_P BQJO_ %Z2_P#H)K*4>67*6G>-
MSB_"WQ U/7/$%O87%M:I%*&),8;/ SW->CUX9\//^1TL?]U__037N=76BHRL
MA4VVM2"^G:VL+B= "T<;. >F0,UYUX?^(FJZMKUK836UHL<S[6**V1^M>@:M
M_P @>]_ZX/\ R->(>"_^1QT[_KH?Y&G2BG%MBFVFCWNBBBL#01F"J23@ 9->
M5ZC\4M1AU&XBM+:T:W1RJ,X;) []:[#QUK(T?PS.4;$]Q^YB^IZG\!FO'8-$
MN)_#]UJZ@F&WD5",=<]3^''YUT48)J\C*<G>R/>]+U"/5-+MKV+&V9 V!V/<
M5<KSKX6ZQYUE<:5(WS0GS(P?[IZ_K7HM8SCRR:-(NZN%><^*O'^IZ%X@GT^W
MM[5XHPI#2!L\@'L:]&KP[XB_\CG>_P"ZG_H(K2C%2E9DU&TM#2_X6MK/_/I8
M_P#?+?\ Q56K?XLW8<?:-,A=>_ER%3^N:ZW0?#FC3Z!82RZ9;/(\"EF*<DXJ
M/6? &BZA:2"VMEM;@ ['CX&?<57-2O9HFT^YI:!XFT_Q';F2S<K(GWX7X9?_
M *U;5> :#>7/A[Q3 V2K1S>5*O9@3@BO?P01D=*SJPY7H5"5T<9XW\77WAJ>
MU2TA@D$RDMYH)Q@^Q%9?ACXBWFK:Y#8W\%M'',"JM&"#N[=353XL_P#'WIW^
MXW\ZXB6TN-,AT[4HR1YH\R-O1E/2MH4XN"ON1*34CZ)HJAHNI1ZOH]K?1GB:
M,,1Z'N/SJ_7*U8V,'Q;X@/AW17NXU1YRP2)'Z$FN"@^*6LRW$49M++#N%.%;
MN?K4?Q+U5M1\01:9 =R6P ('>1O\!C\ZYB[L?[,\0BS)R8I4!/OP3753IQY=
M=S&4G?0^A5.5!]12TB?<7Z4M<IL%>9^(/B3>Z?K=S9V$%K)#"VS?(&)+#KT-
M=MXEU9=%T"[O<CS%3;&#W<\"O$-/T>ZU:RU&^0DBU3S7_P!HD\_IDUO1@G=R
M,YR>R/;O#>M#7M#M[_"K(XQ(B]%8=16O7E/PLU?R;VXTN1OEE'F1Y_O#K7JU
M9U(\LK%1=U<****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,_6-/74M-E@P-^,H?0UYDRLC%6&&4X(/8UZ[7!>+=/^RZC]I08
MCGY/^]WKR,TH7BJJZ;GKY77M)TGUV+G@N^PTUBYX/SI_6NQKRJPNVL;Z&Y4_
M<;)]QWKU*&59H4E0Y5P"#6F65N>ER/=?D9YG1Y*O.MG^8^BBBO3/,"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DW^HD_P!T_P J
M^?=!_P"1HL/^OI?YU]!2*7C=1W!%>9Z;\-=1LM8MKQ[RW9(IA(0 <D UM2DD
MG<SFFVK'I]%%%8F@5F>(_P#D6-5_Z])?_036G5/5;5K_ $B\LT8*\\#QJ3T!
M((IK<3V/&?AY_P CI9?[K_\ H)KW*O._"_P_O]#U^WU":Z@>.(,"J@Y.1BO1
M*TK24I71---+4IZM_P @>]_ZX/\ R->(^"_^1QT[_KH?Y&O<[V!KFQG@4@-)
M&R GMD8KSW0/AWJ&DZ[:W\MW Z0ON*J#DTZ<DHM,4TVT>DUYK\5-9VQ6VCQ-
MR_[Z;'H/NC^OX"O2:\VUWX?:OK>M7%^][;@2-\H.?E4=!4TK*5V.=[61E^#O
M EOKVE-?7TLT2LY6(1X&0.IKHO\ A56C_P#/W=_F/\*[#2M/CTO2[>RCQMA0
M+D=SW-7*<JLF]&"@K'F'B#X;6>GZ)<WEC/<23PKOV.000.O;TK'^&VL?8/$'
MV-VQ%=C:/]X=*]E=%=&1AE6&"/45Y>_PQU&#4C<V5[ B)+OA!!RHSD"KA44H
MN,V2XV::/4J\.^(O_(YWO^XG_H(KVZ/?Y:>9C?@;L=,]Z\^\4^ +_7=>GOX+
MJ"..0* K Y&!BHHR49:E5$VM#K_#@SX:TX'_ )]T_E7EGCWP\^A:TM_:@K;7
M#;T*_P #]2/ZUZYI-H]AI-K:2,&>&)4)'0D"H==TB'7-(GL9L?.,HW]UAT-$
M)\LK] E&Z,WP9XB7Q!HJN[#[5#A)E[Y['\:Z2O/?#'@C6?#NL)=I>V[0L-DT
M8S\Z_P"->A5-1*_NCC>VIY;\6?\ C[T[_<;^==5\/O\ D3;/ZM_.JWC7PC=>
M)I[5[:>*(0J0=^><UL^&-)ET308+"9U=X\Y9>AR:N4E[-(23YFSBOBKI'_'M
MJT:_],I2/T-<3:B[\2ZU86DSEVPD"G^ZBU[CKVE)K6C7-@^ 9%^5C_"W8UR_
M@_P+-X?U1[V\GBF8)MC" \$]350JI0UW1,H-R.UMX$MK>*",82-0JCV%>%^(
M_P#D>[O_ *^Q_,5[S7F^J_#O4+_Q'/J4=W L<DPD"D'..*FC))NY4TVM#T9?
MN+]*X?XG:Q]CT1-/C;$MVV&QV0=?SKN0,*!Z"O/_ !5X'U3Q%K37BW<"1!0D
M:-G(%33MS78Y7MH<QX*\&P^)(KF>[DECAC(5#'CD]ZZS_A56C_\ /W=_F/\
M"NF\-Z,N@Z)!8@AG49D8?Q,>M:U5.K)RT8HP5M3SK4/A=81:?<26ES<M<(A9
M%8C!([=*X[P1JQT?Q/ 9#MBF/DR ^_\ ]>O=J\QU;X97=SK%S=6-U#%!)(9$
M1@<KGG'YU4*ETU-DRA9WB>FYSTI:K:?'<0Z?;Q73J\Z(%=EZ$CO5FN<U"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K+U^P_M#2I449D3YT^HK4HJ*D%.+B^I=.;A)270\AKO/!]ZUQIC6[Y
M+0-@'_9/2JU]X.6>\>6WN!'&YW%"N<'VK<TK2H-)M?)B)9F.7<]6->3@L)6H
MUKRV_,];&XNC6HVCO^1?HHHKV3Q@HHHH **** "BBB@ HHHH **** "BBB@
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MH\[_ )Z.=S#Z>E;=35J\^B"$+:L****Q- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>atha-20220512_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-12T11:25:17.6894+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atha-20220512.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atha-20220512.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-12T11:25:17.3126+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://athira.com/20220512" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:atha="http://athira.com/20220512" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atha-20220512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atha-20220512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>atha-20220512_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-05-12T11:25:17.5520+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140367370857912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Athira Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001620463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3368487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">18706 North Creek Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bothell<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-8501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATHA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>atha-20220512_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atha-20220512.xsd" xlink:type="simple"/>
    <context id="C_72a7fe5e-3498-4d66-be85-930574d9811a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_52e8f171-ac48-4fe5-a2c0-dabeb0dfc465">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_5d21fadd-21e5-40f8-8f16-66cb87413e05">0001620463</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_4c050076-fcfa-44f6-b8b3-5b4172356730">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_ed872b65-829a-4c70-88b8-394e03bab28d">2022-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_639411ca-213a-42fb-a1d1-055fd2852ad1">Athira Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_93914722-d546-4b04-8151-525843b4e3f1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_794c4f27-51dd-4380-8008-5a3664b9dc29">001-39503</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_24c3692b-f2b4-4076-83d6-01d95a2e7700">45-3368487</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_8a348824-bc21-4e4b-a3f4-5bf47eb9ef43">18706 North Creek Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_b993a0ad-9017-42b1-887c-156cffa85f43">Suite 104</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_70720b98-0eea-487d-8daf-be4380cd0140">Bothell</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_84cc91ea-c011-4bab-8472-109b3b2204b2">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_360076d2-def5-40f2-b5d5-074315b4166f">98011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_53162c24-cf8e-4eee-86e7-ed4145c1292a">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_21e5445c-936c-4187-b7f1-0a9d108d653f">620-8501</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_1b27a5cd-05ec-42ac-8325-a395783802e6">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_9167a419-f600-4f09-ac78-98cb1a280e92">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_1ad79437-f353-4bd9-afa4-d6f11728cc91">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_4d017f7c-5370-4bf1-9d32-fa03d1a8b0d2">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_f171ebd7-45bf-4a8c-81b6-6a659f7e9a47">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_9999f1d9-e632-4886-89c3-6b4feef0566d">ATHA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_c593f70f-f938-4923-9ddd-d478ad65cdcf">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_7a67752e-b5d3-4530-ba16-f9535224403a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_72a7fe5e-3498-4d66-be85-930574d9811a"
      id="F_3392c808-fdef-4dbc-804c-c785950cdd4f">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( (6!K%0'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ A8&L5'KZG63N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ A8&L5)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "%@:Q4ZV 8,FX$  "%$0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ A8&L5)^@&_"Q @  X@P   T              ( !L0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "%@:Q4EXJ[',     3 @  "P
M        @ &-#P  7W)E;',O+G)E;'-02P$"% ,4    " "%@:Q4'#AEZC\!
M   \ @  #P              @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ A8&L5"0>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ A8&L5&60>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="atha-20220512.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="atha-20220512.htm">atha-20220512.htm</File>
    <File>atha-20220512.xsd</File>
    <File>atha-20220512_lab.xml</File>
    <File>atha-20220512_pre.xml</File>
    <File>atha-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "atha-20220512.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "atha-20220512.htm"
     ]
    },
    "labelLink": {
     "local": [
      "atha-20220512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "atha-20220512_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "atha-20220512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "atha",
   "nsuri": "http://athira.com/20220512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "atha-20220512.htm",
      "contextRef": "C_72a7fe5e-3498-4d66-be85-930574d9811a",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "atha-20220512.htm",
      "contextRef": "C_72a7fe5e-3498-4d66-be85-930574d9811a",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://athira.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-22-009670-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-009670-xbrl.zip
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M=H*9XUA$T01]"F,6^R&+T&4UY3ZLT>^@HRA"%[)7ABY$)M);P3MRR)\.^SG
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M'R_>1TL^.XIVI>9;%*/Q#TJ+LOC)#_90*(.1.6*@1<O*="GH\"P399$/5?$
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MZQ5/P69(M9K55E>>(3/E5%4%EXDKE=Q1^D=6#]2;>Y346$B6[]4,U?JO,[;
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M6B&\6'Q^"3\^S&>PR#=84IC(O"Y1&""P,:;*HFB[W8;%B@DM>6UL.!WFLHR
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M-19?Q'ESOEO?#MR9# !SRO.:/QUW0^LHK!/Z_G1+&MW9TD[0V^56TMXRYW\
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MPY M[L.]'2!H-1O-IM&X,JSFP+):S:N6]5O]ZJK9^*71:#4:&Z_1V9KA\22
M<^<"Q%N\;4*0YZWA$1.;.-CVH"\;_01=XM2A[7GP)M[RX0WYB"V06X\P/=Z#
MEB>[L?)QRW<F:&H_42>D=UO;Z,]JR+PZ96.SV6A<FLE;N1'B-T.&&>(6[Y]Q
M:=57OEL#/AK$#]O>HQ$9OLK$+R_#:.OZ^MH,GR:A/E8%<EC+_/K\U _[:? 1
M"KAJJ'9W!A#+80^1)X860KP6HQXJH"@>FW'#87R  _%" I/<7\_X;;0*$'&1
M&S:8-$F=5) GY*=,OCEA:!0Q\#F%L'D?.?4Q79@NPIQ&T_KO5W%I1)="X)_Y
MK]\>"">S?I@B-N9?^1^,+H-)ATYG-EE+[)#F;6U7M*F#;H\AWAZ?2 X2LZGK
M^W/$!D(N]CH:(:;@O/,5+<0CY=JNRY#O]P,^I5]9C]$%%E]6GM YX54H_4,:
M:U>W(\3BZV6'NBHU4X^U$.HC9\[$5%DY$YN,T8L]51%3AFDA*/>C'F*8N@_$
M%;N,@J$Z3O^4B7_PU1(U=\V75*Q6-0<<M4#$\'&EVED_H)U5 =4>Y9NM]S>>
MY<SD@F"-9-_0&/L!LTF0,Z^58?K5%.O>*QO0)=DEY4:D%IH#9HNLNK^>#JFG
M()=^KH622&B]WH02]#*?#I7;7"9$ZUYB-8<#D3@6["-)B,9O[6'%!XOX6!P&
MHETB/W',AFHA^A?7AN?4(D69$QR=6WP%2W6<1BT[?)-@MM?EZ=/J3Y2?@6_'
M::0XL%==ES>/1[% N;.E.%XCY4?LY<_I3(B>A)4N$&L/Q>[@!*J,-?5<SS)#
M/>SPJ4G&SSS%8]A6K<N*((T#V24.93/*PN\H/!5UZ)S/A'5AME#\EA;Z;9[]
MN2(#?/3LL8)H^GF:DH@2A@6_$C84(L:7?MHPX!LXG;."<Z3RP/[-&R8CO)>!
M(5!K=Q$B2$B(,"$&O3'?&7Q<+W8=X0_L"H<UG U<B( A0H80NIP.%1WOCQN7
M&/,3A*A &4A<+4-3PJ"4/QJ;]L"!K#NA]AP#!$@Y-%5FP8%T)11(+!!@Y=!6
M.@@'\DY<] @,.%IHCVN8I9NFP@=-T?A"_)$ P6!)R]5?F _'RBXP]&IME:'U
M*]'1BY0]\4'=B#"!@Y:XT*C<B^/XOV.5N-#D&!H?I'RXPO/M5$"6PS_E>1S(
M.L: "*0<GMLNR(%40Q@(<2 "*G?;E-[(H<J*=X&.P&J>#R] HI;Y*6?MDB-S
M]A6\ \9;:#G\E4;*@>1C+$B#E:G[EKMRG.@Q&(1HP.'*9)YCMAS7 PX*:=12
MY^NV(7,<>8%3*MV44W/HZ4%@P#\2Y=^2%L*,=W/HZ2$! HE4YJ=0Z-\<]W6D
MH#?.S'$#)>98*<?GP$XD&"! "GFV6=K8LIDC&^27.]J,(TR'\C/Y+#"BYN/7
M1XQ.=Q>'R,;I?K94U@'3T8%]BTMD+_:RI:KIRC[E)NG!*#"C3F(T]A^'TQ@!
M54F*))PQG*JA6%2D(JGFFD[54"XL6Y&<\QVG$YB,JD(6Y4S,&$[5*KY9VK(M
M=&(MG9:^UK[Z6J="7EG^HF2?-9>JI*\NB$D35_A))Z!XMD1&*?>6G50-<671
MC*2;=8^J(9E71B-Y*MVC:O>_[<*:[;TOY1Q5^<WFE]IL)=9JXZ@:ZH7%-Y)W
MOF%4I=XYY3AIL55N496D=Q3HI,D7&495=B);LI/FO64/593BJXIXDAP_XPM5
MM,CEEO4DRYS:%ZIR^/<J]$E_$;M=HFHZI"S]D=2S+E!(<M/*X?GI][LS>0='
M_^QT]S]02P,$%     @ A8&L5"RTEGFS!   OBP  !4   !A=&AA+3(P,C(P
M-3$R7W!R92YX;6SMFEUSXC84AN_S*U3W9G=:XX\DNQLF9(>2I,,T7P/L=*<W
M'6$+T*PLN9(!\^][9*P4@TR:BW4ZX][$QGHM/7HERT?'N?R<)PRMB%14\)X3
M='P'$1Z)F/)YS_DR=OOCP7#H?+XZN?S!=='U[? !/9 UZD<979%KJB(FU%(2
M]&Y\_QY]_65TA^XH_S;%BJ!K$2T3PC/DHD66I5W/6Z_7G7A&N1)LF4&#JA.)
MQ$.N6U8_D 3KZ^@:9P1U0S\,7?_<#<))$'3#\V[PL?/AT\793[[?]?V=VT2Z
MD72^R-"[Z#W2=T';G!/&-NB6<LPCBAD:FT9_1D,>=5"?,332=RDT(HK(%8D[
MVSH9]*#+3#=R1;LJ6I $WXFHP.LY._W)IY)UA)Q[H>^?>L]WU2KT+]?(7'T)
M^N>>!IU<Q0Z"T>"J:/M?-&+D^8%^?5JH@XN+"Z\H?98J:A-"M8'W]?YN7/33
MA1'*P#7B7)T@M+5#"D9&9(;T\<MH^%P)SA94XF(<M?'^>1!Z&<X%%\G&TV+/
M3 -S[//XAF<TVPSY3,BD<!3PBE86DLQZ#M2)75.;]N7'U]21;5+2<Q1-4D8<
M[Y\>I!)&F6>%5L_14JX9OU-OX+*N>[_A*BC),\)C$A=>&U8FHHJ(Z9DG9-4F
MS:P NI@<BD2=N5AY,:$:/?CK3)^ZV]/"0_CYYT# H]Z?JDSB*#.U,3PEK.<<
MEGM-(!DC)U"KA:A2W A0'YJ+=9.W#,\M1-7R1CUZ(I(*F&^Q7A^/F%75-8*X
M?0A&9$[UY.'9 TYLA%99@X #<$=B-H0G+O^-;&H)]W4-(L++2<A4R&*]&,.R
M009B"32;@8CK+3U^5X/XMY21AV4R);*6=4?2(-@$Y\,8AI7.Z/8U_@)EG;Y!
MY'X<P[M#E0=X=Y"@%M>F?5/4\!6HX1N@#N#T44[$FK\$NJ-L'K-XEA_EDQ0K
MJD.R%UCWY<T#/PD('MD?-#VZ7EG%C<#JT>S#1J,&KU+<")#>5K"GA>#UZ^:!
MI!&PWR7-(#@=B"19\G(15!8ZNZX11-C4T8AFL%N]AWDO89]GX;.(&H%[DD1[
M OMI4H2P.LZ7C[.9=8B/B-\"=JC4DLA7(1_>TLP4(-$2)N F"*<3O>&R38!]
M22-@$XEU&F6\2:;"-BVKY8UZ=9-'"\SGI"9*M\H:?)/<)$3.P9I?I5AG"YAC
M*>;UL;I=W21N#D/)%=7KWG;K5<]Z**V [N8*^K(*C65DZH732M[B,$=4*KP4
M2ZC/C1:4/5/-I$AL^WW3FK!LO9&0\%CW'-]!*6#KV=%S(,1;*J 0J>;5:R_P
MPX,O27RW[7DM7P%7V//?-6 O$U Z$+3(@9K$0^E$V"(G[/F-THC3UAEQD$<I
MG3AKG1,OI&M*7\Y;Y\MN'J@TX4/K3*C-.96.?&R=(]:45NG&I__=T%FSTHV+
MMKJQFY@S,5>;PL[CZ3_C2)O"T&/Y1>-'FX+1:@K3.-"F*/0P9VI<:%,$6I.@
M-5:T*>BT)8*-#VV*.X_EG(T?;8HZ7TYK&U?:%'T>YLR-"VV*.O<2]":KU:98
MT_Y!P#C1OABSYLN#,:1-06;]MPWCQO<*."^] S-@:_SMZJ0LT'_T_[]>_0U0
M2P,$%     @ A8&L5/A$CE"^*@  5O "  \   !A=&AA+65X.3E?,2YH=&WM
M7>EWVT:2_[Y_1;]L,FN_!]$\)%$2,WFK6(KC61\:RYG9_;2O"33)'@-H+ [)
MS%^_5=6X>.BF)("J'+9$XNBNZOI5=74=/\_2P/_EW\3/,R4]^%O\G.K45[^<
M_O?.X6&G]_,;^RM<\":_XN>Q\>9T9222=.ZKO_Z0JN_IC@X]%:9'W4[WI]'$
MA.E.HO]41SWX/4I'@8RG.MQ)371D/_!UJ'9F2D]GZ5&OT]NSMTQDH/WYT5<=
MJ$1\4I?BBPED6-P]-FEJ@OP!]$[IZVEX%.-31C_\\C,^HQC36+K?IK')0F_'
M-;Z)C^+I6+[J.O3OZ]'*9[W7H\N93M5.$DE7'46QVKF,963'=6D'.C:^5Y];
MCT92'_E;&-$XUJ, AGNIO71V--$I#"!,@38PQ-/O,SW6J;"TQ3M_^?E-U"AJ
MNO!>%2,Y=3 52>S^]0?XH;\[[.[V=_M[_]OM_"N:_B"DGZ[_(I^%G7UON!M]
M'^4C.]B'GW_XY2__WMOOCC8_[4&_OZ&)U]?1U8OBOFN@F'_#N?_4PK1[9T(>
MIS,=2W$VDW$@Q1<5F3A-Q&\Z3E+Q]TS&,!'1[_;[\%$H0U=+'RY*,C]-F/@/
M)KZ0H2?.8G.A/9CBF8X44H(^_35+X,<D$7]$GDQ5NZA]D[SW6=[OM^1" U+J
MWXZ4]B(<RY%.X3/W2N)^#D4:PVA%:D1,"  _1;048>U),8E-(([??MTY/D&@
M2)3HBV/_3Z!>H.*__/OW?K=W.$J$IQ.%7R9IYLW%>"X4K&,S$?V_]_NMXAPO
MWY='!%]-6F+^_OKYZ^^G'SXXXI_'CO@HYZ+7=TA%%Y1]>A"Z^R2$A8W=D:B/
M^DYC?Y)Q+IA'CG@?NIUR ;>(VJ\^'9^?'/_]2!Q__?WXM2.D\,&H$"Y(D':E
M#VI"3I48:Q/11%V5I?BY<$T0R7 N)L;-$@5H'@I/72C?1#J$?0T,S!>!\96;
M^2!LI#Z2U,1*A"J+30A/@ VOG\[(I$E\<VF_\-14A2J6J3:A [=YL(IE& +A
M7'A).E/%BROE,BG-3WA%%H#]"8.*Z=K_R\U44#=P]T<9NS,QZ%F9H!='UL*"
M'^H6UKBPL#)K875:A$PO;$/U5."\"5FS2]8=?9W!X*8SDZ6T2">THRJ6*EI%
MN#HOE0BD!R83S%)/0.1@?K!:IS&N2^E=X)('03-9#-,&>5%3$!0W-O"M1:9*
M0 I9+@0T4,6S9) XXE*C%%I!1C&&*833XMF^DI[PXFPJ8 2>1G%PX-)D:D)@
M5(I"BA*#\S#P1UR3>1W2$TK) @R(0*[AY8D >OLHRF&JPPS?!5^ZL4+D\662
M$H0 WJ@9Z$1XZ(7T,^78&7DCF#!<2/+\37S0*8WB;-8YZ8#6^Q54WQD02>.*
MI+&]G6DU$:??85BIOE#B\P3(:2EM*=41!6=.LI@&L\P5!]D196-?)S-XL44.
ME:!U!+\)6&R7>!^Z[O"Q)<'S"\O?%8(-(!G2)LDBLJ?A^A36N$J+-__^[K<W
M'T^_6CQ,8P!>[8IDGJ0JZ CQ3P5C 1B-?+2H/20</#S52+KTTL!=EV1F:\N!
ME:D<T4>%K7[^^_'9:6Z6PT#JC,6[SX#".DQ,N&K*>PJ7D98TQY/B%UI+']3E
M7/QJ: CXK<Q?UZM>!,IFI]?M=W'X"KF+P]>P,!(Y4>D<D=\'+3#6OL;?B(Y6
M_Q@8$-#*I=E9%3(7%\;/@!<J3CK%(FD17C%D-QZRWX> N9Y&JP27+.(:7(0@
M XO4K\RE$J(),2Q,HW%$U\<@[[C.2[Q.K2(@B53?P:I)\/D@'H3J*M1@Q@!!
MP0 CR$Z5#$ 6 #T5&%?P]]K[?C4RILWUB0;D 9,KL5*)X ";?8M9P/T,AC$G
M? >QR1%P,!+O8M0T9]K]IA +T2!$(TF%PM<3&+NK$<"2_$;[:/@Z%H.NF"L)
MCX)7PZ#@;D*Z7">A.4BF)'U?T0(E>YU^LC)_$G?$1^W.I/(!B\(_92SQBVKX
M%PH@#3Z@801H7J8S^+5?&\O;3^=6@=6U'[W6!(&*T7#4?Y*]61MV9YT-_WQ&
MNA MDF6&L\;#&1@18%P)WZ VG>)VZ1)!HW3R68MLV<^'Z%(Z^:S/SRITT,37
M./W&<PM4E<O/8AB)FXL.13&5&H4ZP8FB8H>/\!9K#)"P*C3:I#LO4"X$S/'Q
M2A5?H.D!TEL#1A.E.@ :T5, 0/UYHA,PF0 :<&M(9JE)R63Q_3F8J!<&H%%\
M>/];-2MK:^4F*EFO.9SC0V%:.D!*26)Z:6Z9&$$1KAWGAB2^MO8F0/XPF2 G
MR10-E*?=W#;&H0(3?9@*X59I*\.+I(N@#82\FLR5=0Q#=OT,-[4(G]8^;AB>
MM4B4&<V>Q-EY=Y_QXD$D8L07A?YJ\3N\P"<D.5HBLJ<OBCGE9,#I'@TZ@\'@
MI]$*Y4&R #+F1Q-??:]3/3_.6R'[O\ FT9-Y,4:Z#_UG<3HBXNX 38+D: S2
MBO>N944UV_JHFJ=I5I;56BXMD+2DIPZ)=$36.[WD&@+7Z;:[.SSL'?9V]WK=
M_<'A\*="\?7[I=355L+BJ)I"WQN]SZ5/5*<"E P0&A1LX4(PX=3@SY\CL-L_
MR#&HRE.\@/8)5F<7+M)"YZ$ Y4J]M,?3&+16LN(8P%MAD!X(PTY@< L$AOPU
MF@E4/VR2<#RP[J<:]TLU1Y 1,WEAW;J^0C6G-#F2Z.5V&Z#\W$Z(@-6@,"/R
M%H0+4S4X59^FJHJIHAL!+(5+L&I<A?HVB_"3W@%L%<)T1C/#^W;L?2DZH&A[
M0-N)^IPKN(:5D_^Y042Y L<94!A0G@I0SDI_9K&<Q"E:UJ!5??*VGA5FK'AU
M^N7LM3@;=+MT5A2ZUD3/91H]@^A:)K=EM7E 65W8-$CK_3X^>7-V B;1WH L
MUXF*E;6QX?MD9B[S4Q][3_&*R$29G^_9P]CX/KDT%CR;!!^(C+"CL5.S)C>Z
M6ZVE?2-^U=YRA?@WV6I[(L-U%A<OC.14[8P!0[_MR EZFJ5_*><)W-AV4G7O
MB597D.QZI<$ZXH$ZXD(GVAX<',VT!^OL.?7$UN@'1'A 4QE%L8EB>]Q4.[LA
M#\]D@G;:LKD(_X'"6- 7Z%6>@/F*V(I&GAG_"^ZT'A&99#'!]*6)R3L5@#Z)
MY^B%=E62T-%@I)37I"B+8U0V-[L[FC#4V_!9E6>E!9.L/I[ASGJ.WON8C(+\
M9,$UTY".1MA*;@8"LI7\6-)1^I;4XL$^V;DD(VC]AO:$SQJ:RIW)4"<!0IJT
MPI3;H+* O%2.#>@KM7H$GY1GA)%)M+W<>(55"I<7P0(HMK&-OD=+>"%V( ]T
MRL7TH@!JNE"BSYK.+0L;&3WIN6D.UC &GHASXVITQ./&_Y3.R'"7#'=]HM?
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M5)8%@L\^@Y4SMEV'>O90=SBL:@*5B1)W@:Z\/&EO5R0ZK4HF+X;D4FTD#-"
M&<B.^(JI%K$.,-I7A1Y%=%#$;SYF,/(PYW-*!UYEJ/Z'S:6^YS6[$X6A4_51
M)/E#\,HR*]LIWV=#CHN<KZOVW@P@#""M!)"\(T>L JE#*F6_IG?13E74=+$P
MJ8T?08E:KL7/@L*"LEV"8O5462(K;T5@2\QB.P,,/BRK=GTJSGK>AT#!-,,Z
M!:"?;8N(R167D%LX3ZB!^8,P'5.)X4]9@!K\2[=W_*Z[W]\_L.I4AWE17'AR
MU5F!E#%6T*6F%['R;;(C#-CXRK?2"U]%Z+*V%7^JI@ZDZCP# PD-!AVC I4Q
M4*<J"&;K!V)A8:0#9DTFMYK09IW6O!]=//G,ZU$6AP5WVI">M'E#>G"PVSOD
M#2FK25:3S5"37Y0;9SHM=J3U:KFEZLS+S[*)R&M_J]9^;D3I$+MR)0M%6!.)
M+AF!3[9&(GHWBC/][QJL.+3-=C']J]X1(4EC%4[A,6'^K++6@8C,I=UMN6;G
MFYJO<VS4XQ>.3X[/=]Z:*4R+Q8[%;IO$[FO5X)**OY6-X7(_:%[U356N4MJP
M+'49*?J9E-U94.!0H%=<&[8&P8)79*%IW$SZD_S: 6]['M%H7ENIW^Y]VKB9
M.3C8!R'ES0QK%M8LS= L[T/QMPPP'L_.'%&:=[9S*-7[NPZ"/G\X_>_7'?$;
M:!U;RVI1'Z'"Z._#<-6W6A<-C#TUGO"JIJK%]JDZ*[,M1IPUG4'<H@0A]88U
M>1LN8[43CB>O>6H[>US3NZ,H9XK5BX5GT#TT[(I@^L:3\]=T;F?;@LBJQR/H
MSOZ^P.DD'?$^O% )%5 TRW79[%&#P.8F7E[DH!P'+H)(R 3CN>I;2!/#3,.R
MNPJ;L PT6P4T=1,VIHY<_F(+=Q#'=3V+?-H=%FCB9G&,0K,6E"P<B;Q-'[[0
M4ZZFK[2M:NP70F=;G]()@Z<B%=K$&:K*BKDG-M'E(T %"#>.Q-91>'5R_O%7
MQ(8"[C">,C!@$-L9"5MDD4HZ%\5:R7KNB-/;M#BZ#@L?U/%(!'*^F8Y''2X=
MP<"T=< 4R'^!G-MSPELU([NB15J1YT)7VW)\ZX45D8HWSH^X05NL]E:>%CZX
MJ%L[M]V#7O^@Q]MN5CJL=)JA=/*-MG>;DI7YH2)LU&68X>D'!9_E7U+F4 R0
M9;"QM>? (S-07CNT]W2*>L_T9ML0ST%U).$G?\=N10N,C&)C)COP'UR+&4)5
MW;[ERIB+)SK#O36QMK?!6;!PKX19WOZRP&^5P-_S!*? @(4C&SZ#><1TTJ)(
M::M:"9 6N&>WF"MS2XL>4LD\ =C+/32)&"O*]/<N)#EN;*F?L@ELY3JH2INC
M+W6EO"LL1NWFI0RV, GU1<C0[0WWHA9PN1'[/6]M\H^JM4D+=U9[O?W#_2'O
MK-C08D.K(:IP]0CSJH9+E)I7:/L%TVHYT8?.$A;+F5]J4*$+;6YM=2P'M*B/
M97(H[\!FUN7%L SLB!1U0ZS50E_=3^T?E'V?YD#>:>[X]U3LUSM!M;-$3BM*
M 32C*@(7D&C_JFEKE:E[];DLX97.40'C:$-2;B.6.]5BU$11KN? 'J+87PY?
MXTYDK&H97[#S.%.QCK"E++:7C>$Q1??95V>?SE_;J,5CVUWVH^TNRQ8-6S1;
M9-&0Q5&D*&*%ZW4-9=$0R2+7!+A'!\%8)Q>V.PN((YHX"PV>4YV2A]@Z;=W1
M.3D*/A:.@D*2SPI)_EA(LCBEGK+P&=@H7Y27N<#,,_0Z?*&.\!Y6^LP[RM+;
MO\!83[0<HSUDVT5'$BV>C]@;UK'O]T88UO51SD5OSZD98G:NL2KR4W$DN;.L
M&&'57;MHII;[WBIW]"1+L:H"K(<P60@E4]\CWP9]7(=<:#Q2BVM1ZW-==VK4
M,Q.B"KL6W![C^,GVC)M8B$O*LDUV9S-+,_ZF0QE2EO$7VR"VP;4967VR^GQR
M]?EPN_2M3&:YPC)AF\"V(W#HCG!Q NK_,GTA?8I&HCJ.%'L<V.@D!6KLQT&W
MU^EC,KRO;=M/T(@?9>S.Q*!GE:>SU KXQT'OL#-<NN5$N8HJ,>1W]>PP1);8
MN@NFK#\L+N&.'WO[G?WR$:@34=<6[A/;%?6&40P[@Y4'K//"<%(? ],V 1-H
M?$628</-JN+<K[[\10;1Z.2U./T>J3!1:ZV"YL)6/GRJ#HZCSP&JM]O9NT'0
M;XD7NRN/2;"W<IY6 B!E<<O6C[%YR@167JRQ'XDMT8857\9S>'A"^1IVDY*:
M6F;SDK<XK[2K\T9A^47PTL2$(9Z[6EPNOZAMSI8ITA$<1,U8MD58]DZ%M+DE
M)YX'5VDLBDA;YE?O:/$?5VC6:55D13[\930[Z!QN LP&:XR?-6#FU$#+R]0B
M3I405(P1D\N,:P^_RCR7%?_'3$G/!7JG>;%P3&@K$]TJB"/?R H1[+CZEAAY
MN2W8O]I:#8BHZX: AUQSK-&E79T[G. Y+HZ=RE!>,UAI'5A):MQO,X-G82*P
MSBS$W0KF-<*[F6!13,K62U1\H=$758Q\Y?)QEF"3N&2E/T9Q-6D%'ZY GF(^
M39K4J:/Q<4D6RZ+WU42Z>/2'H>)$"DZ88:S?)JS_I%+QP20M,TIQU#Y6]*5=
M*YB'W0)W,6!._-CM[.TCDHID!O#L/ #3I0B+=P$:UA5%\:;^WKW>U+L229KM
M>GVB<^YF$Z&9LGP\-EE:)/W;-G$.F %NY\73=H/G=I:N1%:'K*Y<QHM"IDJ<
M*YFFOL(S+: _Q?+B?K3<@:*>F2HQUF9M6[TY8(A+#CJST$AW,<PWL?6.P80"
MDXVB<=% LI%&9+@DOKFT7WAJ2@8]&F6=LFZJ#N@1V*!+>V#QR4A[135Q,/1U
M0/T^R7["Q\%S\[:[8&7&"1W1%1T_[9&ES0?)$T8PD]K&"U1G=YA&[2X, DNH
MVPQPC'"F$.0B#3LJVES9H\#R2*X,0P:SK8JZKQ\6TJC2&(@+E]M@9PO+:RJ)
M4C_%FW-;G*LS6ZQ-N1(.37%BZX\)Q6_8NQS95BN'ZX@+G>A4/%[,[#K+:^^.
M(G!Y>=F1Q+H.K-4G#I/=C.7P/R:CFB/23TR>^5^L1A"WIR3_/5IC4?*7^=9"
MPCL-)^T''7Y3WONPA:0EK/E/*Y96H31_)7\%& 5]TE9J-YNX6,Q<3F/92H!N
ME:G*>Z'&[H7 R,).!#L?C*$>.]3CAT[8'RTHITD-$MO"Z,WDXNJJ;01^3'UA
MBJ#'2;X0_'PA).5"*,,2T:;/]VZ!@KV*[7AQGKNQ^\/C,GD7MEZQ=08?N^0>
M[QT.!DYU:>]TS:6GW_,^4=4]NV4@XUFL+W!S6+O^@Z8R=/C +PIW"-6-AWMT
M$)I0$N85TZ)82NR&,9;Y)A+H@W6O<)>&+42+HTT_\U3]OEA-X8GXL,6Z>E=E
MA%ZQI\HW3\Y&-E8V)K.X//^P3+:Y=FC7I:B.<IN_&ED$6W2B=0K[U1!WM7.[
MB:N>3KM0&-DH#S;=PC379N1_<*H,I\JT20'5SQHI 'U419O8ZJ53&V<^K_H
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MTL#_Y?\!4$L! A0#%     @ A8&L5,4KSR^R%0  $.L  !$
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B82UE>#DY7S$N:'1M4$L%!@     %  4 00$  "!/      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
